DRW Securities’s Travere Therapeutics TVTX Stock Holding History

DRW Securities’s Portfolio TVTX Stock Details TVTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$312K	Buy	+10,518	New	+$314K	﹤0.01%	868
2024 Q3	–	Sell	-11,598	Closed	-$95.3K	–	746
2024 Q2	$95.3K	Buy	+11,598	New	+$78.1K	﹤0.01%	495
2021 Q1	–	Sell	-100,000	Closed	-$2.73M	–	221
2020 Q4	$2.73M	Sell	100,000 -20,000	-17%	-$467K	0.1%	47
2020 Q3	$2.21M	Hold	120,000	–	–	0.12%	49
2020 Q2	$2.45M	Sell	120,000 -82	-0.1%	-$1.31K	0.11%	56
2020 Q1	$1.75M	Sell	120,082 -60,000	-33%	-$903K	0.06%	63
2019 Q4	$2.56M	Hold	180,082	–	–	0.1%	63
2019 Q3	$2.09M	Buy	+180,082	New	+$2.98M	0.14%	50
2016 Q1	–	Sell	-17,500	Closed	-$338K	–	91
2015 Q4	$338K	Buy	+17,500	New	+$350K	0.03%	60

Other funds holding TVTX

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

NAMI

Nomura Asset Management International Philadelphia, Pennsylvania $58.4B AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

DRW Securities's TVTX Position: Q1 2026 in Review

DRW Securities opened a new position in Travere Therapeutics (TVTX) in Q1 2026: 10,518 shares worth $312K. The stake represents ﹤0.01% of the portfolio and ranks #868 among its holdings. This is a return to the name: DRW Securities previously reported a position in TVTX as recently as Q2 2024.

DRW Securities first reported a position in TVTX in Q4 2015 and has held it in 9 quarters since. The position peaked at $2.73M in Q4 2020. 260 funds tracked by Wall St. Rank hold TVTX as of Q1 2026.

DRW Securities held 10,518 shares of Travere Therapeutics worth $312K as of Q1 2026.
Travere Therapeutics was a new DRW Securities position in Q1 2026.
Travere Therapeutics made up ﹤0.01% of DRW Securities's portfolio in Q1 2026, its #868 holding.
DRW Securities first reported a position in Travere Therapeutics in Q4 2015 and has held it in 9 quarters since.
DRW Securities's Travere Therapeutics position peaked at $2.73M in Q4 2020.
260 funds tracked by Wall St. Rank held Travere Therapeutics as of Q1 2026.

Based on DRW Securities's 13F filing for Q1 2026, filed 13 May 2026.